StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics cash

Cash and short-term investments held at the end of each period.

Protara Therapeutics's cash was $142.49M at Jun 30, 2026. For fiscal 2025 it was $155.55M, down 9.1% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $171.04M in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$155.55M-9.1%
FY2024Dec 31, 2024$171.04M+157.9%
FY2023Dec 31, 2023$66.33M-22.1%
FY2022Dec 31, 2022$85.12M-7.5%
FY2021Dec 31, 2021$91.97M-45.7%
FY2020Dec 31, 2020$169.39M+2632.1%
FY2019Dec 31, 2019$6.20M-71.7%
FY2018Dec 31, 2018$21.90M-48.0%
FY2017Dec 31, 2017$42.10M+1.9%
FY2016Dec 31, 2016$41.30M-36.8%
FY2015Dec 31, 2015$65.30M-21.9%
FY2014Dec 31, 2014$83.60M+2893.2%
FY2013Dec 31, 2013$2.79M+15.9%
FY2012Dec 31, 2012$2.41M-26.3%
FY2011Dec 31, 2011$3.27M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$142.49M+15.9%
Q1 FY2026Mar 31, 2026$135.79M+8.5%
Q4 FY2025Dec 31, 2025$155.55M-9.1%
Q3 FY2025Sep 30, 2025$132.67M+61.3%
Q2 FY2025Jun 30, 2025$122.96M+36.1%
Q1 FY2025Mar 31, 2025$125.11M+123.5%
Q4 FY2024Dec 31, 2024$171.04M+157.9%
Q3 FY2024Sep 30, 2024$82.24M+10.0%
Q2 FY2024Jun 30, 2024$90.33M+11.4%
Q1 FY2024Mar 31, 2024$55.97M-35.9%
Q4 FY2023Dec 31, 2023$66.33M-22.1%
Q3 FY2023Sep 30, 2023$74.78M-23.0%
Q2 FY2023Jun 30, 2023$81.11M-18.2%
Q1 FY2023Mar 31, 2023$87.36M-1.1%
Q4 FY2022Dec 31, 2022$85.12M-7.5%
Q3 FY2022Sep 30, 2022$97.06M+3.5%
Q2 FY2022Jun 30, 2022$99.20M+16.1%
Q1 FY2022Mar 31, 2022$88.34M+3.8%
Q4 FY2021Dec 31, 2021$91.97M-45.7%
Q3 FY2021Sep 30, 2021$93.76M-43.5%
Q2 FY2021Jun 30, 2021$85.41M+185.0%
Q1 FY2021Mar 31, 2021$85.14M+135.7%
Q4 FY2020Dec 31, 2020$169.39M+2632.1%
Q3 FY2020Sep 30, 2020$165.91M+1683.9%
Q2 FY2020Jun 30, 2020$29.97M+177.5%
Q1 FY2020Mar 31, 2020$36.12M+115.0%
Q4 FY2019Dec 31, 2019$6.20M-71.7%
Q3 FY2019Sep 30, 2019$9.30M-64.5%
Q2 FY2019Jun 30, 2019$10.80M-59.2%
Q1 FY2019Mar 31, 2019$16.80M-54.3%
Q4 FY2018Dec 31, 2018$21.90M-48.0%
Q3 FY2018Sep 30, 2018$26.20M-44.7%
Q2 FY2018Jun 30, 2018$26.50M-16.4%
Q1 FY2018Mar 31, 2018$36.80M+7.9%
Q4 FY2017Dec 31, 2017$42.10M+1.9%
Q3 FY2017Sep 30, 2017$47.40M+0.9%
Q2 FY2017Jun 30, 2017$31.70M–
Q1 FY2017Mar 31, 2017$34.10M–
Q4 FY2016Dec 31, 2016$41.30M–
Q3 FY2016Sep 30, 2016$47.00M–

More Protara Therapeutics figures

See a number that looks wrong?